• Sorry! To unlock all site features, we'll need to collect some information from you.
  • Unit 5.2: Diagnosis and Management of Unstable Angina/Non-ST Elevation MI

    Christopher P. Cannon, MD — Brigham and Womens Hospital

    Duration:1 hour


    Faculty Disclosure

    • Grant and/or Research: Merck; Sanofi-Aventis; AstraZeneca; Merck-Schering Plough
    • Consultant: AstraZeneca; Bristol-Myers Squibb; Glaxo Smith Kline; Merck; Merck/Schering-Plough Partnership; Pfizer; Sanofi-Aventis; Schering Plough; BestMed; i3 Magnifi; NCME; BGB New York
    • Speakers’ Bureau: AstraZeneca; Bristol Myers Squibb; Guilford Pharmaceuticals; Merck; Millennium; Pfizer; Sanofi-Aventis; Schering Plough


    Learning Objectives

    • Discuss the pathophysiology of UA/NSTEMI and atherothrombosis
    • Illustrate the steps in risk stratification
    • Give examples of current recommendations for anti-ischemic and antithrombotic therapy
    • Debate the benefits of an invasive vs. conservative strategy
    • Give examples of recommendations for risk factor modification and long-term medical therapy